CRISPR Therapeutics

Update in progress

CRSP (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

CRISPR Therapeutics AG is a gene-editing company using CRISPR/Cas9 technology to develop medicines for serious diseases. Its lead candidate, CASGEVY, edits patients’ hematopoietic stem cells to raise fetal hemoglobin for transfusion-dependent beta-thalassemia, severe SCD, and related hemoglobinopathies. It also advances CAR T therapies (CTX112, CTX131), in vivo editing (CTX310, CTX320), and allogeneic hypoimmune stem cell programs (CTX211), with Vertex as a partner. Founded in 2013 and based in Zug, Switzerland.

Company score

Sentiment: 0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.23; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.10; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationSwitzerland
CEODr. Samarth Kulkarni Ph.D.
Founded2013
Websitewww.crisprtx.com

Identifiers

ISINCH0334081137
FIGIBBG00DBBGRX1
LEI506700O6IRRIQLT3W370
CUSIPH17182108
CIK0001674416